{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:55:53Z","timestamp":1774655753214,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ygyno.2014.03.016","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T20:30:07Z","timestamp":1395433807000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Circulating and disseminated tumor cells in ovarian cancer: A systematic review"],"prefix":"10.1016","volume":"133","author":[{"given":"Nuria","family":"Romero-Laorden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-3601","authenticated-orcid":false,"given":"Jesus","family":"Garcia-Donas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Diaz-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.03.016_bb0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0010","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0015","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba5503","volume":"31","author":"Du Bois","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0020","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer","volume":"24","author":"Markman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/annonc\/mdn601","article-title":"Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels","volume":"20","author":"Prat","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12094-012-0756-8","article-title":"Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls","volume":"14","author":"Diaz-Padilla","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0090-8258(90)90088-3","article-title":"Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment","volume":"38","author":"Cain","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.2001.19.2.368","article-title":"Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse","volume":"19","author":"Braun","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0050","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","article-title":"Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0055","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2907","article-title":"Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment","volume":"13","author":"Giuliano","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0060","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0065","first-page":"2629","article-title":"A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients\u2014a meta-analysis","volume":"12","author":"Wang","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0070","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2010.01.008","article-title":"Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer","volume":"138","author":"Rahbari","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0075","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0095","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2007.07.073","article-title":"Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer","volume":"107","author":"Wimberger","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0105","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.25602","article-title":"Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients","volume":"128","author":"Wimberger","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0110","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/IGC.0b013e3181a23c4c","article-title":"Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies","volume":"19","author":"Banys","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","article-title":"Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer","volume":"112","author":"Fan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ygyno.2006.05.049","article-title":"Detection of disseminated tumor cells in patients with gynecological cancers","volume":"103","author":"Fehm","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2003.08.004","article-title":"Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer","volume":"91","author":"Judson","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1525-1438.2007.00920.x","article-title":"Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow","volume":"17","author":"Schindlbeck","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/cncr.10250","article-title":"Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis","volume":"94","author":"Marth","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance \u2014 a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0145","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0150","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ijc.23825","article-title":"Review: biological relevance of disseminated tumor cells in cancer patients","volume":"123","author":"Riethdorf","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0155","first-page":"929","article-title":"Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer","volume":"15","author":"Ross","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0160","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V","article-title":"Distant metastases in epithelial ovarian carcinoma","volume":"60","author":"Dauplat","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0170","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-12-1587","article-title":"Meta-analysis of the prognostic value of circulating tumor cells in breast cancer","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.05.007","article-title":"The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer","volume":"130","author":"Glaser","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0180","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2006.07.7800","article-title":"Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer","volume":"25","author":"Axtell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/gyno.2000.5749","article-title":"The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma","volume":"77","author":"Chi","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2009.06.021","article-title":"A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172","volume":"115","author":"Krivak","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2003.12.043","article-title":"The predictive and prognostic value of serum CA 125 half-life during paclitaxel\/platinum-based chemotherapy in patients with advanced ovarian carcinoma","volume":"93","author":"Gadducci","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2008.01.035","article-title":"Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel\/platinum chemotherapy: a French multicentric study","volume":"109","author":"Riedinger","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0205","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/jnci\/djr282","article-title":"Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer","volume":"103","author":"Lee","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0210","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2013.08.006","article-title":"Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients","volume":"131","author":"Liu","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0215","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","article-title":"Circulating tumour cells in cancer patients: challenges and perspectives","volume":"16","author":"Pantel","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0220","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2010.34.0026","article-title":"Circulating tumor cells: not all detected cells are bad and not all bad cells are detected","volume":"29","author":"Wicha","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.016_bb0225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-012-9398-0","article-title":"Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials","volume":"32","author":"Bidard","year":"2013","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.ygyno.2014.03.016_bb1000","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cncr.22076","article-title":"A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation","volume":"107","author":"Fehm","year":"2006","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:57:47Z","timestamp":1565279867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0090825814002522"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating and disseminated tumor cells in ovarian cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}